. 2022 Aug 23;82(12):1287–1302. doi: 10.1007/s40265-022-01756-6

Table 4.

Number of events per study, sorted by study population

References	Study	Antithrombotic regimen^a			Sample size			MACE			MB			MALE			ALI
References	Study	T1	T2	T3	N1	N2	N3	N1	N2	N3	N1	N2	N3	N1	N2	N3	N1	N2	N3
Studies on patients who are solely selected for PAD
[13]	CAPRIE	A	C		3229	3223		277	215
[39]	CHARISMA	A	A+C		1551	1545		138	117		27	26
[40]	CLIPS	A	P		185	181		9	19
[16, 41]	COMPASS	A	A+R1	R2	2504	2492	2474	174	126	149	42	68	66	56	32	40	34	19	19
[42]	COOPER	C	TP1		215	216		0	2
[35]	EUCLID	C	TG2		6955	6930		740	751		109	113					115	117
[45]	Gresele	A	A+CC		73	74		0	0
[55]	WAVE	A	A+ VKA1		1081	1080		144	132		24	74					44	42
Cumulative incidence of events with universal comparator A, n (%)								742/8623 (8.6%)			93/5136 (1.8%)			56/2504 (1.6%)			78/3583 (2.2%)
Studies on patients who underwent a peripheral vascular intervention for PAD
[36]	Becquemin	P	TP2		121	122		31	28								17	16
[15]	BOA	A	VKA2		1324	1326		275	248		56	108
[37]	CABBAGE	A	A+CI		25	25		2	1		0	1		2	3
[38]	CASPAR	A	A+C		426	425					5	9		151	149
[44]	ePAD	A+C	A+E		101	100		1	3		2	0
[46]	Johnson	A	A+VKA1		413	418					15	35
[47]	Li	C	C+VKA1		25	25		2	1		0	1
[48]	MIRROR	A	A+C		40	40		15	12
[49]	Monaco	A+C	C+VKA1		157	161		5	7		13	15
[52]	RIVAL-PAD	A+C	A+R1		11	9					0	0
[53]	Soga	A+TP1	A+TP1+CI		39	39		3	1		0	0
[54]	STOP-IC	A	A+CI		98	93		9	11					28	16
[17]	VOYAGER-PAD	A	A+R1		3278	3286		588	514		100	140		770	687		227	155
Cumulative incidence of events with universal comparator A, n (%)								889/4765 (18.7%)			676/5466 (12.4%)			951/3827 (24.8%)			277/3287 (8.4%)
Studies on patients with coronary artery disease who coincide with PAD
[43]	CREDO	A	A+C		140	132		24	12
[50]	PEGASUS TIMI 54	A	A+TG1	A+TG2	404	368	371	71	47	54	4	4	5	26	23	17	4	2	3
[51]	PLATO	A+C	A+TG2		578	566		112	93		46	58
Cumulative incidence of events with universal comparator A, n (%)								95/544 (17.5%)			4/404 (0.9%)			26/404 (6.4%)			4/404 (0.9%)

ALI acute limb event, INR international normalized ratio, MACE major adverse cardiovascular events, MALE major adverse limb events, MB major bleeding, Nx number of patients in group x PAD peripheral arterial disease, Tx treatment in group x

^aAntithrombotic regimen: A acetylsalicylic acid 75–325 mg daily, C clopidogrel 75 mg once daily, CC cloricromene 100 mg twice daily, CI cilostazol 200 mg once daily, E edoxaban 60 mg once daily, P placebo only, R1 rivaroxaban 2.5 mg twice daily, R2 rivaroxaban 5 mg twice daily, TG1 ticagrelor 60 mg twice daily, TG2 ticagrelor 90 mg twice daily, TP1 ticlopidine 200 mg twice daily, TP2 ticlopidine 250 mg twice daily, VKA1 vitamin K antagonist with target INR between 1.4 and 3, VKA2 vitamin K antagonist with target INR between 3 and 4.5